Evidence map›Paper›PMID 31298656›Full record

ArticleeLife2019

Agnes Ulfig, Anton V Schulz, Alexandra Müller, Natalie Lupilov, Lars I Leichert

Open access · goldAbstract read
In one paragraph

Article in eLife, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 32 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Biotransformation of the Novel Myeloperoxidase Inhibitor AZD4831 in Preclinical Species and Humans.Drug metabolism and disposition: the biological fate of chemicals · 2023
    Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Agnes UlfigInstitute of Biochemistry and Pathobiochemistry - Microbial Biochemistry, Ruhr University Bochum, Bochum, Germany.
Anton V SchulzInstitute of Biochemistry and Pathobiochemistry - Microbial Biochemistry, Ruhr University Bochum, Bochum, Germany.
Alexandra MüllerInstitute of Biochemistry and Pathobiochemistry - Microbial Biochemistry, Ruhr University Bochum, Bochum, Germany.
Natalie LupilovInstitute of Biochemistry and Pathobiochemistry - Microbial Biochemistry, Ruhr University Bochum, Bochum, Germany.
Lars I LeichertInstitute of Biochemistry and Pathobiochemistry - Microbial Biochemistry, Ruhr University Bochum, Bochum, Germany.ORCID 0000-0002-5666-9681
Ruhr University Bochum · DE

Funding

Deutsche Forschungsgemeinschaft LE2905/1-2
6 · The paper itself

Abstract

Hypochlorous acid (HOCl), a powerful antimicrobial oxidant, is produced by neutrophils to fight infections. Here, we show that

Indexed as

HalogenationAcyltransferasesAntigens, BacterialAntioxidantsBacterial ProteinsBlood ProteinsCell Line, TumorChloraminesHumansHydrophobic and Hydrophilic InteractionsHypochlorous AcidImmunoglobulin GImmunologic FactorsMaleNADPH OxidasesNeutrophil ActivationAcyltransferasesantigen 85B, Mycobacterium tuberculosisAntigens, BacterialAntioxidantsBacterial ProteinsBlood ProteinschloramineChloraminesHypochlorous AcidImmunoglobulin GImmunologic FactorsNADPH OxidasesPhosphatidylinositol 3-KinasesProtein AggregatesSerum AlbuminStaurosporinebiochemistrychaperonechemical biologyhumanhypochlorous acidimmunologyinflammationN-chlorinationoxidative damageplasma proteinsserum albumin

Identifiers

PMID31298656
PMCPMC6650281
OpenAlexW2961490968

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.